ARIH2 and bladder transitional cell carcinoma: Together, our findings uncover an ARIH2-NUPR1 regulatory axis that drives BLCA progression by suppressing ferroptosis and favouring an immunosuppressive microenvironment, highlighting this pathway as a potential therapeutic target in BLCA.